STAT+: New data point to benefits of Bristol’s novel psoriasis pill, but safety issues will be scrutinized

Last November and then again in February, Bristol Myers Squibb said its oral drug designed to treat psoriasis differently from currently approved medicines had achieved the goals of large Phase 3 clinical trials.

On Friday, the actual data from those two studies were presented publicly for the first time at the annual meeting of the American Academy of Dermatology. The Bristol drug, called deucravacitinib, proved more effective at clearing the chronic skin disease — numerically and statistically — compared to a placebo and a competing drug from Amgen.

Continue to STAT+ to read the full story…